AQR Capital Management, LLC, AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC jointly filed Amendment No. 2 to a Schedule 13G on November 16, 2026, disclosing beneficial ownership of Class A ordinary shares of Translational Development Acquisition Corp. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each of the three AQR entities reported beneficial ownership of 974,300 Class A ordinary shares, representing 5.05% of the class.
  • No sole voting or dispositive power: All 974,300 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0 for all three entities.
  • Event date: The date of the event requiring this filing is stated as September 30, 2026.
  • Entity relationships: According to the filing, AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC is deemed to be controlled by AQR Capital Management, LLC.
  • Security covered: The filing covers Class A ordinary shares with a par value of $0.0001 per share, CUSIP G9008W105.
  • Certification language: The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

AQR Entities Disclose Joint 5.05% Position in Translational Development Acquisition Corp.

Three affiliated entities under the AQR umbrella filed Amendment No. 2 to Schedule 13G with the SEC on November 16, 2026, covering their holdings in Translational Development Acquisition Corp., whose principal executive offices are listed at 52 E 83rd St., New York, New York 10028. The filing reports a triggering event date of September 30, 2026.

According to the filing, each of AQR Capital Management, LLC (classified as an investment adviser), AQR Capital Management Holdings, LLC (classified as a holding company), and AQR Arbitrage, LLC (classified as an investment adviser) beneficially owns 974,300 Class A ordinary shares, amounting to 5.05% of the outstanding class. All three entities report zero sole voting power and zero sole dispositive power, with shared voting and shared dispositive power each totaling 974,300 shares. The filing does not indicate that these shares are held on behalf of another person, as Item 6 is marked "Not Applicable."

The AQR entities' principal business offices are located at One Greenwich Plaza, Suite 130, Greenwich, Connecticut 06830. Henry Parkin signed the filing as Authorized Signatory on behalf of all three entities. The exhibit included in the filing states that AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC and that AQR Arbitrage, LLC is deemed to be controlled by AQR Capital Management, LLC. The filing does not name a specific exchange or ticker symbol for the issuer's shares.

What Was Disclosed

Three AQR-affiliated entities filed an amended Schedule 13G disclosing aggregate beneficial ownership of 974,300 Class A ordinary shares, or 5.05%, of Translational Development Acquisition Corp., with all voting and dispositive power held on a shared basis as of September 30, 2026.